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Immunity to WT1 in the animal model and in patients with
acute myeloid leukemia
Alexander Gaiger, Valerie Reese, Mary L. Disis, and MartinA. Cheever
The Wilms’tumor (WT1) gene participates
in leukemogenesis and is overexpressed
in most types of leukemia in humans.
WT1 is also detectable in many types of
lung, thyroid, breast, testicular, and ovar-
ian cancers and melanoma in humans.
Initial studies evaluated whether immune
responses to murine WT1 can be elicited
in mice. Murine and human WT1 are simi-
lar. Thus, mouse models might lead to
resolution of many of the critical issues
for developing WT1 vaccines. C57/BL6
(B6) mice were injected with synthetic
peptides from the natural sequence of
WT1 containing motifs for binding to ma-
jor histocompatibility (MHC) class II mol-
ecules. Immunization induced helper T-
cellresponsesspeciﬁcfortheimmunizing
WT1 peptides and antibody responses
speciﬁc for WT1 protein. Screening of
multiple murine cancer cell lines identi-
ﬁed 2 murine cancers, TRAMP-C and
BLKSV40,that“naturally”overexpressWT1.
Immunization with MHC class I binding pep-
tides induced WT1 peptide-speciﬁc cyto-
toxic T-lymphocyte (CTL) that speciﬁcally
lysedTRAMP-CandBLKSV40.WT1speci-
ﬁcity of lysis was conﬁrmed by cold tar-
get inhibition. No toxicity was noted by
histopathologic evaluation in the WT1
peptide-immunized animals. WT1 peptide
immunization did not show any effect on
TRAMP-C tumor growth in vivo. Immuni-
zation of B6 mice to syngeneic TRAMP-C
elicited WT1-speciﬁc antibody, demon-
strating that WT1 can be immunogenic in
the context of cancer cells. To evaluate
whether WT1 might be similarly immuno-
genic in humans, serum from patients
with leukemia was evaluated for pre-
existingantibodyresponses.Westernblot
analyses showed WT1-speciﬁc antibod-
ies directed against the N-terminus por-
tion of the WT1 protein in the sera of 3 of
18 patients with acute myeloid leukemia
(AML). (Blood. 2000;96:1480-1489)
© 2000 by TheAmerican Society of Hematology
Introduction
Many candidate antigens are “self” proteins expressed by normal
and malignant cells. These self-antigens have included proteins
expressed during fetal development—but only on rare adult tissues
(ie,MAGE-1andHER-2/neu)—andproteinsrelatedtothedifferen-
tiated function of the involved tissue of malignant origin (ie,
tyrosinase and gp100).1-3 The Wilms’ tumor (WT1) protein is a
self-protein expressed in a time- and tissue-speciﬁc manner during
embryogenesis.4 WT1 is expressed in the adult, but only in low
amounts in the nuclei of some normal tissues, such as hematopoi-
etic precursor, kidney, and gonadal cells.4-6 Recent studies demon-
strated that the WT1 gene is overexpressed in most types of adult
leukemia, including acute myeloid leukemia (AML), chronic
myeloid leukemia, and acute lymphocytic leukemia and in some
patients with myelodysplastic syndromes.7-15 WT1 is also ex-
pressed in many types of lung, thyroid, breast, testicular, and
ovarian carcinomas and in melanoma.16-21
The WT1 gene is located on chromosome 11p13 and was
originally identiﬁed in sporadic and hereditary cases of Wilms’
tumor.5,22 The gene consists of 10 exons, and it encodes a zinc
ﬁnger transcription factor. As a result of alternative splicing,
several WT1 mRNA species are expressed that exhibit different
DNA-binding speciﬁcities.23,24 During embryogenesis the WT1
gene is involved in the regulation of growth and differentiation, and
it interacts with a variety of target genes.25 WT1 binds to the early
growth response-1 DNA consensus sequences in growth factor
gene promoters, such as the platelet-derived growth factor A chain
promoter and the insulin-like growth factor II promoter.26-28 In
Wilms’ tumor, WT1 expression is found in the malignant counter-
parts of cell types that express the gene during normal kidney
development. It has been suggested that aberrant expression of the
WT1 gene product leads to uncontrolled proliferation, with aber-
rant differentiation and eventual tumor formation.4
There is a theoretic advantage for targeting antitumor immune
responses against proteins necessary for maintenance of the
malignant phenotype. We chose to evaluate WT1 as a candidate
tumor antigen because WT1 protein is more abundant in leukemia
cells than in normal hematopoietic cells,11,29 WT1 seems to
participate in leukemogenesis, and WT1 protein expression may be
necessary to maintain the viability of leukemia cells.30-33 WT1
function might similarly be necessary to maintain the viability of
human solid tumors in which it is overexpressed.
Immunologic tolerance to self-proteins can prevent or dampen
the development of immune responses to many putative self-cancer
antigens. The objective of the current study was to initiate an
evaluation of WT1 as a tumor antigen. WT1 is highly homologous
in mice and humans (96% at the amino acid level) and has similar
tissue distribution and function.34,35 Thus, mouse models might
resolve many of the critical issues for developing WT1 vaccines.
Results demonstrate that antibody, helper T cells, and cytotoxic
T-lymphocytes (CTL) speciﬁc for WT1 can be elicited in mice.
WT1 peptide immunization did not show any effect on TRAMP-C
tumor growth in vivo. The lack of observable in vivo antitumor
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immunization may result from the low major histocompatibility
complex (MHC) class I expression of TRAMP-C cells. Further
experiments are required for better understanding of the therapeutic
potential ofWT1 vaccines in animal models. Preliminary studies to
evaluate immunogenicity of WT1 in humans demonstrated that
antibody responses to WT1 are detectable in some patients with
AML. The extent to which helper T-cell and CTL responses can be
elicited in humans should be evaluated.
Materials and methods
Mice
Female C57BL/6 (B6) mice, 6 to 8 weeks old, were obtained from Jackson
Laboratory (Bar Harbor, ME). Animals were maintained at the University
of WashingtonAnimal Facilities under speciﬁc pathogen-free conditions.
Tumor cell lines
TRAMP-C is an SV40-induced transgenic prostate cancer cell line of B6
origin and was provided by Dr Norman Greenberg. BLKSV40 is a B6
murine ﬁbroblast line transformed by SV40. LSTRA is a Moloney murine
virus-induced leukemia of BALB/c origin. EL-4 is a methylcholanthrene-
induced thymoma of C57BL mouse origin. The human leukemia cell line
K562 was obtained from theAmerican Type Culture Collection (Manassas,
VA).
Peptides
WT1-derived peptides were selected according to the known consensus
motifs for peptide bound by H-2Kb and H-2Db from the naturally occurring
sequences of murine and human WT1.36 Sequences of the CTLpeptides are
shown in Table 1. Peptides used for eliciting antibody and proliferative
T-cell responses were identiﬁed according to the Tsites program, which
searches for peptide motifs that have the potential to elicitTh responses.37,38
Vaccine A consisted of p6-22, RDLNALLPAVPSLGGGG (murine WT1
contains an S at position 16); p117-139, PSQASSGQARMFPNAPYLP-
SCLE (identical between mouse and human); and p244-262,
GATLKGVAAGSSSSVKWTE (murine WT1 contains an M at position
250). Vaccine B consisted of p287-301, RIHTHGVFRGIQDVR (identical
between mouse and human); p299-313, DVRRVPGVAPTLVRS (murine
WT1 contains an S at position 304); and p421-435, CQKKFARS-
DELVRHH (identical between mouse and human). Of note, peptide
p117-139 contained motifs appropriate for binding to murine MHC class I
and II. Peptides were synthesized on a peptide synthesizer (430 A; Applied
Biosystems, Foster City, CA) as previously described.39 The composition
and purity of the peptides were ascertained by mass spectroscopy and
high-performance liquid chromatography analysis. Peptides were deter-
mined to be more than 90% pure.
Peptide-binding assay
The ability of synthetic WT1 peptides to bind to Db or Kb class I molecules
was detected by using the leukemia cell line RMA-S, as described
previously.40 In brief, RMA-S cells were cultured for 7 hours at 26°C in
complete medium supplemented with 1% fetal calf serum. A total of 106
RMA-S cells were added to each well of a 24-well plate and incubated
either alone or with the designated peptide (25 g/mL) for 16 hours at 26°C
and for an additional 3 hours at 37°C in complete medium. Cells were then
washed 3 times and stained with ﬂuorescein isothiocyanate-conjugated
anti-Db or anti-Kb antibody (Pharmingen, San Diego, CA). Labeled cells
were washed twice, resuspended, and ﬁxed in 500 mL phosphate-buffered
saline with 1% paraformaldehyde and were analyzed for ﬂuorescence
intensity in a ﬂow cytometer (FACScalibur; Becton Dickinson, Franklin
Lakes, NJ).The percentage of increase of Db or Kb molecules on the surface
of the RMA-S cells was measured by increased mean ﬂuorescence intensity
of cells incubated with peptide compared with that of cells incubated in
medium alone.
Immunization protocols
For tumor immunization, mice were inoculated twice at 2-week intervals by
subcutaneous injection with 5 3 106 WT1 overexpressing TRAMP-C cells.
For peptide immunization, mice were inoculated 3 times at 3-week intervals
by subcutaneous injection with complete Freund’s adjuvant alone or
emulsiﬁed with WT1 peptides (100 mg). Three weeks after the ﬁnal
immunization, sera were obtained and single-cell suspensions of spleens
were prepared in RPMI 1640 medium (Gibco BRL Life Technologies,
Rockville, MD) with 25 mmol/L b-2-mercaptoethanol, 200 U penicillin/
mL, 10 mmol/L L-glutamine, and 10% fetal bovine serum.
T-cell proliferation assay
Lymphocytes were cultured in 96-well plates at 2 3 105 cells per well with
4 3 105 irradiated (30 Gy) syngeneic spleen cells and the designated
peptide. The proliferative T-cell responses were evaluated using standard
thymidine incorporation as the read out.41 T-cell clones were generated
under similar conditions by a limiting dilution method, as described
previously.42
Cytotoxicity assay
A standard chromium release assay was used,43 and 106 target cells were
incubated at 37°C with 150 mCi 51Cr for 90 minutes in the presence or
absence of speciﬁc peptides. Cells were washed 3 times and resuspended in
RPMI with 5% fetal bovine serum. For the assay, 1045 1 Cr-labeled target
cells were incubated with different concentrations of effector cells in a ﬁnal
volume of 200 mL in U-bottomed, 96-well plates. Supernatants were
removed after 4 to 7 hours at 37°C, and the percentage speciﬁc lysis was
Table 1. RMA-S binding
Name Sequence
RMA-S binding
H-2Db (%) H-2Kb (%)
WT1 peptides with motifs predictive of binding
P136-144 SCLESQPTI 27 1
P221-229 YSSDNLYQM 1 1
P225-233 NLYQMTSQL 6 1
P228-236 QMTSQLECM 1 1
P235-243 CMTWNQMNL 34 1
P239-247 NQMNLGATL 1 1
P329-337 GCNKRYFKL 1 1
All 9mer WT1 peptides within p117-139
P117-125 PSQASSGQA 2 7
P118-126 SQASSGQAR 2 7
P119-127 QASSGQARM 2 6
P120-128 ASSGQARMF 1 7
P121-129 SSGQARMFP 1 7
P122-130 SGQARMFPN 1 7
P123-131 GQARMFPNA 1 7
P124-132 QARMFPNAP 1 9
P125-133 ARMFPNAPY 1 8
P126-134 RMFPNAPYL 79 65
P127-135 MFPNAPYLP 2 8
P128-136 FPNAPYLPS 1 5
P129-137 PNAPYLPSC 1 4
P130-138 NAPYLPSCL 79 94
P131-139 APYLPSCLE 1 9
Isotype control 1 2
No peptide 1 6
Peptide binding to C57BL/6 murine MHC was conﬁrmed using the RMA-S
binding assay. Samples were analyzed using the Becton-Dickinson FACScalibur.The
positive region was gated to contain approximately 1% of the RMA-S cells stained
with isotype only. The same region was used to determine the percentage positive for
class I stained samples.
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Release 2 Spontaneous Release) / (Maximum Release 2 Spontaneous
Release) 3 100.
Cold target inhibition
Effector cells were plated for indicated effector:target ratios in 96-well
U-bottom plates.A10-fold excess (compared to hot target) of the indicated
peptide-coated target without 51Cr labeling was added. Finally, 1045 1 Cr-
labeled target cells per well were added, and the plates were incubated at
37°C for 4 hours. The total volume per well was 200 mL.
Antibody blocking experiments
Effector cells were plated for indicated effector:target ratios in 96-well
U-bottom plates.Antibodies were used at 25 mg/mLﬁnal concentration and
were added to peptide-coated 51Cr-labeled target cells 5 minutes before
plating with effectors. For control antibodies, IgG2a k isotype standard
(Pharmingen) and I-Ad/b MHC class II alloantigen antibody (Pharmingen)
were used. For Db-speciﬁc antibody, anti-H–2Db (Pharmingen) was used,
and for Kb-speciﬁc antibody, anti-H–2Kb (Pharmingen) was used.
TRAMP-C tumor challenge experiment
B6 mice were vaccinated with 100 mg peptide plus complete Freund’s
adjuvant, 100 mL of a 1:1 mixture injected subcutaneously and boosted
twice at 3-week intervals. Control mice were injected with adjuvant only or
were left untreated. Three weeks after the ﬁnal immunization, mice were
anesthetized with Metofane (Schering-Plough Animal Health, Union, NJ),
shaved on the right ﬂank, and injected subcutaneously with 106 TRAMP-C
cells in 100 mL saline. TRAMP-C was grown to approximately 70%
conﬂuence before harvest. Mice were monitored for tumor growth, and
tumors were measured on 2 axes with calipers.
Recombinant protein puriﬁcation
For protein expression, cDNA constructs representing the human WT1
full-length (aa 1 to aa 449), the N-terminus (aa 1 to aa 249) and the
C-terminus (aa 267 to aa 449) regions were subcloned into a modiﬁed
pET28 vector. The resultant vector has a 59 His tag followed by the
thioredoxin (Trx) coding region, followed by a 39 histidine tag, followed by
a thrombin and EK site. Recombinant BL21 pLysS Escherichia coli
(Stratagene, La Jolla, CA) containing the expression constructs for the
TRX-WT1 protein and the fusion proteins of truncated forms of WT1 with
TRX were grown overnight and induced with isopropyl-b-D-thiogalacto-
side. All the proteins behaved similarly and were puriﬁed essentially
according to this protocol: cells were harvested and lysed by incubation in
10 mmol/LTris, pH 8, with complete protease inhibitor tablets (Boehringer
Mannheim Biochemicals, Indianapolis, IN) at 37°C followed by repeated
rounds of sonication. Inclusion bodies obtained were washed twice with 10
mmol/L Tris, pH 8/0.5% CHAPS, and solubilized in 8 mol/L urea
containing 10 mmol/L Tris at pH 8 (buffer A). Proteins were then puriﬁed
by metal chelate afﬁnity chromatography over nickel-nitrilotriacetic acid
resin (QIAGEN, Valencia, CA) as described.44 Proteins were analyzed by
SDS-PAGE, and fractions containing the protein of interest were pooled
and dialyzed overnight against excess 10 mmol/L Tris, pH 8. Dialysates
were brought to 8 mol/L urea and were loaded onto a Source Q anion
exchange resin (Amersham Pharmacia Biotech, Uppsala, Sweden) equili-
brated in bufferA. Proteins were eluted in bufferAwith a gradient from 0 to
1 mol/L NaCl. Fractions containing the proteins of interest were pooled,
dialyzed overnight against excess 10 mmol/L Tris, pH 8, and stored at
280°C for further use. The identity of the WT1 proteins was conﬁrmed by
N-terminal sequencing.
Antibody responses
Antibody responses to WT1 were determined by Western blot analysis
using both recombinant full-length and truncated WT1 proteins and a
WT1 polypeptide, WT N180 (Santa Cruz Biotechnology, Santa Cruz,
CA). Western blot analysis was performed as described.41 As the
primary antibody, sera from immunized as well as nonimmunized B6
mice or patients with AML was used in a 1:500 dilution with
Tris-buffered saline/1% bovine serum albumin and 0.1% NP-40. A
polyclonal antimouse or antihuman-horseradish peroxidase-conjugated
second antibody (Amersham Pharmacia Biotech, Piscataway, NJ) was
used in a 1:10 000 dilution. Blots were then developed with an enhanced
chemiluminescence reaction (ECL; Amersham); after that, they were
exposed to Hyperﬁlm-ECL (Amersham). The ﬁlm was developed and
examined. All control blots were developed by using the commercially
prepared WT1-speciﬁc antibodies WT C-19 and WT 180 (Santa Cruz
Biotechnology), and they demonstrated a strong band at the expected
size of the TRX-WT1 fusion proteins (TRX-WT1 full length, approxi-
mately 85 kd; TRX-WT1 N-terminus, approximately 60 kd; TRX-WT1
C-terminus, 50 kd).
Semiquantitative real-time RT-PCR
Bone marrow (BM) aspirates were obtained from patients with AML at
diagnosis at the First Department of Internal Medicine, Division of
Hematology, University of Vienna, Austria, where they were also treated.
Leukemia was classiﬁed according to the French–American–British classi-
ﬁcation criteria after examination of the BM aspirates stained by a modiﬁed
Wright technique. Mononuclear cells were isolated by density-gradient
centrifugation using Lymphoprep (Nycomed, Oslo, Norway), and cell
pellets were frozen immediately at 270°C. Total RNA was extracted as
described previously. To assess the quality of RNA, all RNA samples were
analyzed on denaturing formamide agarose. We took precautions to prevent
contamination, as described earlier.12,45 cDNA was synthesized with
oligo-dT primer (Boehringer Mannheim, Indianapolis, IN) and Superscript
II RT (Gibco). Real-time RT-PCR was performed on an ABI 7700
instrument using the SYBR green assay system (Applied Biosystems,
Foster City, CA). The reaction was performed in a total volume of 25 mL
that included 2.5 mL SYBR green buffer, 2 mL 1:10 diluted ﬁrst-strand
cDNA template, and 300 nmol/L each of WT1 forward (human, 59-
TGGACAGAAGGGCAGAGCA-39; mouse, 59-TCTTCCGAGGCAT-
TCAGGAT-39) and reverse (human, 59-GGATGGGCGTTGTGTGGT-39;
mouse, 59-ATGCTGACCGGACAAGAGTTG-39) primers that were de-
signed to meet thermal cycler requirements. The reaction mix also
contained 3 mmol/L MgCl2, 0.25 U AmpErase UNG, 0.625 U Amplitaq
gold(PerkinElmer,Norwalk,CT),0.08%glycerol,0.05%gelatin,0.0001%
Tween 20, and 1 mmol/LdNTPmix. Human b-actin primers were obtained
from Perkin Elmer/Applied Biosystems and were used in a similar manner
to quantitate the presence of b-actin in the samples. The sequences of the
mouseb-actinprimerswereforward59-GGCGCTTTTGACTCAGGATT-39
and reverse 59-GGGATGTTTGCTCCAACCAA-39.
PCR was performed using the universal thermal cycling protocol
provided by Applie Biosystems. Fluorescence was measured on the ABI
7700 instrument, and the threshold cycle (Ct) was determined. All samples
were run in triplicate. To quantitate the amount of speciﬁc RNA in the
sample, a standard curve was generated alongside the unknown samples
using semilogarithmic dilutions of K562 (human) or TRAMP-C (mouse)
cDNA. In addition, a standard curve was generated for b-actin ranging from
200 fg to 2 ng. This enabled standardization of the initial RNAcontent of a
tissue sample to the amount of b-actin for comparison. WT1 gene
expression was expressed as an n-fold difference relative to peripheral
blood mononuclear cells (PBMC).
Enrichment of human hematopoietic cells
After informed consent was obtained, CD341 cells were positively selected
from the peripheral blood of healthy volunteers following the subcutaneous
administration of granulocyte colony-stimulating factor (G-CSF) using a
direct magnetic labeling system (Miltenyi Biotec, Auburn, CA).46 The
population was determined by ﬂow cytometry (FACScalibur; Becton
Dickinson) to contain more than 95% CD341 cells.
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WT1-speciﬁc mRNA is overexpressed in human
and murine malignancies
Recent studies demonstrated that the WT1 gene is overexpressed in
most types of adult leukemia.7-15 To conﬁrm these data using a
semiquantitative real-time RT-PCR assay, WT1 gene expression was
assessedinnormalBM,puriﬁedCD341cells,and9patientswithAML.
Controls included K562, a leukemia cell line known to overexpress
WT1. Results were expressed relative to WT1 expression by normal
PBMC.MostpatientswithAMLwereshowntoexpresshigherlevelsof
WT1-speciﬁc mRNA than normal PBMC and BM (Figure 1). WT1
gene expression was also detectable in human CD341cells. However, 7
of 9 patients with AML (patients 1-5, 8, 9) and the leukemia cell line
K562 showed substantial overexpression of WT1 mRNA compared to
95% pure CD341 cells. Two of 9 patients showed similar (patient 7) or
lower (patient 6)WT1 expression compared to CD341cells.
To investigate whetherWT1 expression in murine malignancies and
normal murine BM is similar to that observed in humans, WT1 gene
expression was assessed in normal BM, murine cancers, and leukemia
cell lines. Results were expressed relative toWT1 expression by normal
murine PBMC.Two murine cell lines,TRAMP-C and BLKSV40, were
shown to express high levels of WT1-speciﬁc mRNA compared to
normal murine PBMC and BM (Figure 2). TRAMP-C is a prostate
cancer cell line derived from mice transgenic for the prostate expression
of SV40 using a probasin promoter. BLKSV40 is a B6 ﬁbroblast line
transformed by SV40. EL-4, a carcinogen-induced thymoma, and
LSTRA, a murine leukemia virus-induced leukemia, expressed very
low levels of WT1. S49.1, a murine T-cell–like lymphoma, MethA, a
murine sarcoma, and P3.6.2.8.1, a murine myeloma cell line, wereWT1
negative.
The relative overexpression of WT1 by tumor or leukemia
samples compared to normal PBMC was similar in human and
murine malignancies (Figures 1 and 2).
Immunizing mice to WT1 peptides can induce proliferative
T-cell responses to the immunizing peptide and antibody
to WT1 protein
To determine whether immunity to WT1 can be induced by peptide
immunization, B6 mice were immunized with groups of WT1
peptides derived from the natural sequence of WT1. The peptides
had motifs appropriate for binding to MHC class II molecules and,
thus, eliciting helper T-cell responses. Vaccine A consisted of 3
peptides from within the amino terminus portion of the protein
(exon I, p6-22 and p117-139; exon V, ﬁrst alternative splice,
p244-262). Vaccine B consisted of 3 peptides from within the
carboxy terminus portion of the protein (exon 7, zinc ﬁnger I,
p287-301, and p299-313; exon 10, zinc ﬁnger IV, p421-435).
Peptide sequences are shown in “Material and methods.”
Proliferative responses were evaluated using spleen cells from 4
mice in 2 replicate experiments.After in vivo immunization, the initial 3
in vitro stimulations were carried out using all 3 peptides of vaccineAor
B. Vaccine A elicited proliferative T-cell responses to the immunizing
peptides p6-22 and p117-139, with stimulation indices varying between
3 and 8 (bulk lines). No proliferative response to p244-262 (Figure 3A)
or to vaccine B was detected (Figure 3B).
Subsequent in vitro stimulations were carried out as single
peptide stimulations using only p6-22 and p117-139 (data not
shown). Stimulation of the vaccine A–speciﬁc T-cell line with
p117-139 resulted in proliferation to p117-139 and no response to
p6-22. Clones derived from the line were speciﬁc for p117-139. In
Figure 2. Detection of WT1 overexpression in murine malignancies by real-time
PCR. Total mRNA from murine cancers and leukemia cell lines was reverse
transcribed to cDNA, and WT1 gene expression was determined by semiquantitative
real-time RT-PCR. Results are expressed relative to normal murine PBMC. Mean
values of triplicates are depicted. PBMC and BM values represent the means of 3
different samples derived from normal B6 mice. TRAMP-C, SV40-transformed
prostate; BM, murine BM; PBMC, murine PBMC; EL-4, carcinogen-induced thy-
moma; LSTRA, MuLV-induced leukemia; BLKSV40 HD2, SV40-transformed ﬁbro-
blast; S49.1, lymphoma, T-cell-like; MethA, sarcoma; P3.6.2.8.1, myeloma.
Figure 3. Immunization of mice with WT1 vaccine A, but not vaccine B, induces
proliferative T-cell responses. Three weeks after the third immunization, spleen
cells of mice that had been inoculated with vaccineAor vaccine B were cultured with
medium alone (medium) or spleen cells and medium (B6/no antigen), B6 spleen cells
pulsed with the peptides p6-22, p117-139, p244-262 (vaccine A) or p287-301,
p299-313, p421-435 (vaccine B) at 25 mg/mL, and were assayed after 96 hours for
proliferation by (3H) thymidine incorporation. Bars represent the mean stimulation
index (SI), which is calculated as the mean of the experimental wells divided by the
mean of the control (B6 spleen cells with no antigen) and standard deviations.
Figure 1. Detection of WT1 overexpression in human leukemias by real-time
PCR. Total mRNA from BM, PBMC, cell lines, and human leukemias were reverse
transcribed to cDNA, and WT1 gene expression was determined by semiquantitative
real-time RT-PCR. Results are expressed relative to normal PBMC. Mean values of
triplicates are depicted. PBMC and BM values represent the means of 3 different
samples derived from healthy human donors. K562, human leukemia, chronic
myeloid leukemia; U937, human lymphoma; . 95% CD341, more than 95% pure
CD341 cells; BM, human bone marrow; PBMC, human PBMC; CD151, more than
90% pure CD151 cells;AML1 throughAML9, bone marrow from patients withAMLat
the time of diagnosis.
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p6-22 resulted in proliferation to p6-22 and no response to
p117-139. Clones derived from the line were speciﬁc for p6-22
(data not shown).
Immunization with vaccine A, under the same conditions that
elicited the proliferative T-cell responses above, also elicited
antibodies to WT1 (Figure 4). Sera from mice obtained 3 weeks
after the third immunization contained antibodies speciﬁc forWT1.
As a negative control, sera of nonimmunized B6 mice showed no
reaction against the WT1. No antibodies were detected after
immunization with vaccine B (data not shown), which is consistent
with the lack of helper T-cell response from immunization with
vaccine B. Subsequent experiments demonstrated that the WT1-
speciﬁc antibody responses were predominately of the immuno-
globulin IgG2a type (data not shown).
Immunizing mice to WT1 peptides can elicit WT1-speciﬁc
cytotoxic T-lymphocyte capable of lysing WT1-positive
cancer cells
Peptides with motifs appropriate for binding to H-2b were con-
structed and tested for their ability to bind. Peptides for the
immunization study were chosen according to ability to actually
bind to H-2b using the RMA-S binding assay.40 Results shown in
Table 1 show that some, but not all, chosen WT1 peptides bind to
MHC class I molecules.
Mice were immunized to 9-mer MHC class I binding peptides
p136-144, p225-233, p235-243, and the 23-mer peptide p117-139.
The natural sequences of peptides p225-233, p235-243, and
p117-139 are identical between murine and human WT1, and
p136-144 differs in one amino acid. After immunization, spleen
cells were stimulated in vitro with each of the 4 peptides and were
tested for their ability to lyse targets incubated with WT1 peptides.
CTL were generated speciﬁcally for p136-144, p235-243, and
p117-139, but not for p225-233. CTL data for p235-243 and
p117-139 are presented in Figure 5. Data for peptides p136-144 and
p225-233 are not depicted.
The above WT1 peptide-speciﬁc CTLs were tested for their
ability to lyse WT1 positive versus negative tumor cell lines. CTL
speciﬁc for p235-243 lysed targets incubated with the p235-243
peptides but failed to lyse cell lines that expressed WT1 proteins
(Figure 5A). In marked contrast, CTL speciﬁc for p117-139 lysed
targets incubated with p117-139 peptides and also lysed malignant
cells expressing WT1 (Figure 5B). As a negative control, CTL
speciﬁc for p117-139 did not lyse WT1-negative EL-4. CTL
responses were evaluated using spleen cells from 4 mice in 3
experiments. P117-139 peptide- and tumor-speciﬁc responses were
conﬁrmed in 8 chromium release assays performed at different
time points.
Speciﬁcity of WT1 speciﬁc lysis was conﬁrmed by cold target
inhibition (Figure 6). Lysis of TRAMP-C by p117-139–speciﬁc CTL
was blocked from 58% to 36% by EL-4 incubated with the relevant
peptide p117-139, but not with EL-4 incubated with an irrelevant
peptide (Figure 6A). Similarly, lysis of BLKSV40 was blocked from
18% to 0% by EL-4 incubated with the relevant peptide p117-139
(Figure 6B). Results validate that WT1 peptide-speciﬁc CTL speciﬁ-
cally kill malignant cells by recognizing processedWT1.
Figure 4. Detection of WT1-speciﬁc antibodies in B6 mice immunized with WT1
peptides. Three weeks after the third immunization with vaccine A, sera were
obtained. Lanes 1, 3, and 5 show the molecular weight marker (MWM); lanes 2, 4,
and 6 show the WT1 polypeptide WT N180 (180 amino acids in length, mapping
within the amino terminus domain of the WT1 protein). The primary antibodies used
were WT180 in lane 2, sera of nonimmunized B6 mice in lane 4, and sera of B6 mice
immunized with the vaccineAin lane 6.
Figure 5. P117-139–speciﬁc CTL lyse WT1-positive tumor cells. Three weeks
after the third immunization, spleen cells of mice that had been inoculated with the
peptides p235-243 or p117-139 were stimulated in vitro with the relevant peptide and
tested for their ability to lyse targets incubated with WT1 peptides and WT1-positive
and -negative tumor cells. Bars represent the mean percentage speciﬁc lysis and
standard deviations in chromium release assays performed in triplicate with effector:
target (E:T) ratios of 25:1, 5:1, and 1:1. (A) Cytotoxic activity of the p235-243–speciﬁc
T-cell line against the WT1-negative cell line EL-4 (EL-4, WT1 negative); EL-4 pulsed
with the relevant (used for immunization and for restimulation) peptide p235-243
(EL-4 1 p235-243); EL-4 pulsed with the irrelevant peptides p117-139 (EL-4 1 p117-
139), p126-134 (EL-4 1 p126-134) or p130-138 (EL-4 1 p130-138), and the WT1-
positive tumor cells BLKSV40 (BLKSV40, WT1 positive) and TRAMP-C (TRAMP-C,
WT1 positive). (B) Cytotoxic activity of the p117-139 speciﬁc T-cell line against EL-4;
EL-4 pulsed with the relevant peptide P117-139 (EL-4 1 p117-139) and EL-4 pulsed
withtheirrelevantpeptidesp123-131(EL-4 1 p123-131),orp128-136(EL-4 1 p128-
136); BLKSV40 and TRAMP-C.
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syngeneic and allogeneic T cells. Data shown in Figure 7 demon-
strate that BLKSV40 (Figure 7A) and TRAMP-C (Figure 7B) are
not lysed by syngeneic B6Tcells stimulated for 5 days in vitro with
allogeneic Balb/c cells. As a positive control, allogeneic Balb/c T
cells stimulated in vitro for 5 days with B6 cells and CTL speciﬁc
for p117-139 lysed the WT1-expressing cell lines.
The p117-139 speciﬁc line was characterized in more detail by
antibody blocking tests and ﬂow cytometry.The lytic activity of the
p117-139 line was blocked from 40% to 0% by Db-speciﬁc
antibodies but not by Kb, I-Ad/b–speciﬁc, or isotype control
antibodies (Figure 8). This line was determined by ﬂow cytometry
to contain more than 90% CD81 cells (data not shown).
Several segments with putative CTL motifs are contained
within p117-139. To determine the precise sequence of the CTL
epitope, all potential 9-mer peptides within p117-139 were synthe-
sized (Table 1). Two of these peptides (p126-134 and p130-138)
were shown to bind to H-2b class I molecules (Table 1). CTL
Figure 6. Speciﬁcity of lysis of WT1-positive tumor cells is demonstrated by
cold target inhibition. Bars represent the mean percentage of speciﬁc lysis and
standard deviations in chromium release assays performed in triplicate with E:T
ratios of 25:1, 5:1, and 1:1. (A) Cytotoxic activity of the p117-139 speciﬁc T-cell line
against the WT1-negative cell line EL-4 (EL-4, WT1-negative); the WT1-positive
tumor cell line TRAMP-C (TRAMP-C, WT1-positive); TRAMP-C cells incubated with
a 10-fold excess (compared to the hot target) of EL-4 cells pulsed with the relevant
peptide p117-139 (TRAMP-C 1 p117-139 cold target) without 51Cr labeling and
TRAMP-C cells incubated with EL-4 pulsed with an irrelevant peptide without 51Cr
labeling (TRAMP-C 1 irrelevant cold target). (B) Cytotoxic activity of the p117-139–
speciﬁc T-cell line against the WT1-negative cell line EL-4 (EL-4, WT1 negative); the
WT1-positive tumor cell line BLKSV40 (BLKSV40, WT1 positive); BLKSV40 cells
incubated with the relevant cold target (BLKSV40 1 p117-139 cold target), and
BLKSV40 cells incubated with the irrelevant cold target (BLKSV40 1 irrelevant
cold target).
Figure 7. Controls for lysis of BLKSV40 and TRAMP-C. For syngeneic controls,
3 3 106 B6 effector cells were grown for 5 days with 1 3 106 irradiated Balb/c
stimulator cells. For allogeneic controls, 3 3 106 Balb/c effector cells were grown for 5
days with 1 3 106 irradiated B6 stimulator cells. Lines represent the mean percent-
age speciﬁc lysis and standard deviations in chromium release assays performed in
triplicate with E:T ratios of 50:1, 10:1, and 2:1. Cytotoxic activity of syngeneic and
allogeneic T cells and the p117-139–speciﬁc T-cell line against WT1-positive
BLKSV40 cells (A) and TRAMP-C cells (B).
Figure 8. Inhibition of p117 lytic activity by MHC class I–speciﬁc antibodies.
Lines represent the mean percentage speciﬁc lysis and standard deviations in
chromium release assays performed in triplicate with E:T ratios of 25:1, 5:1, and 1:1.
Cytotoxic activity of the p117-139–speciﬁc T-cell line against the WT1-negative cell
lineEL-4(EL-4,WT1negative);EL-4pulsedwiththepeptidep117-139(EL-4 1 p117-
139); EL-4 1 p117-139 incubated with the isotype control antibody (isotype) (IgG2a k
isotype standard; Pharmingen); EL-4 1 p117-139 incubated with Db-speciﬁc anti-
body (Db) (anti-H-2Db; Pharmingen); EL-4 1 p117-139 incubated with Kb-speciﬁc
antibody (Kb) (anti-H-2Kb; Pharmingen); EL-4 1 p117-139 incubated with the I-Ad/b
MHC class II alloantigen antibody (I-Ad/b) (anti I-Adb; Pharmingen).
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with p126-134 and p130-138, but not the other 9-mer peptides
within p117-139 (Figure 9A).
The p117-139–speciﬁc CTL line was restimulated with either
p126-134 or p130-138. After restimulation with p126-134 or
p130-138, both T-cell lines demonstrated peptide-speciﬁc lysis, but
only p130-138 speciﬁc CTLshowed lysis of a WT1-positive tumor
cell line (Figures 9B), thus indicating that p130-138 is likely to be
the naturally processed epitope.
Toxicity of WT1 peptide immunization
Mice immunized with WT1 peptides were evaluated for toxicity by
observation twice a week for 3 months and by histopathologic
analysis 20 days after the last immunization. Tissues examined
histologically included adrenal gland, brain, cecum, colon, duode-
num, eye, femur and marrow, gallbladder, heart, ileum, jejunum,
kidney, larynx, lacrimal gland, liver, lung, lymph node, muscle,
esophagus, ovary, pancreas, parathyroid, salivary gland, sternum
and marrow, spleen, stomach, thymus, trachea, thyroid, urinary
bladder, and uterus. No evidence for autoimmune toxicity was
observable in any of the tissues examined. Special emphasis was
put on the evaluation of potential hematopoietic toxicity. The
myeloid:erythroid ratio in sternum and femur marrow was normal.
To investigate the potential occurrence of pancytopenia as a late
side effect, peripheral blood samples of 4 WT1 peptide-immunized
mice were analyzed 6 months after the initial immunization. All
evaluable blood cell counts were within the normal ranges (mean
WBC, 8.65 3 103; range, 5.4-10.3 3 103; normal range, 5.4-
16.0 3 103; differential WBC counts all within the normal range;
mean hematocrit, 0.45; range, 0.44-0.46; normal range, 0.32-0.54;
platelets, not evaluable because of clumping).
Tumor prevention experiment
We next investigated whether immunization with either the p117-
139 or the p130-138 peptide elicited immunity capable of prevent-
ing the growth of TRAMP-C. Mice were left untreated (group 1),
given adjuvant only (group 2), 100 mg peptide p117-139 plus
Freund’s adjuvant (group 3), or 100 mg peptide p130-138 plus
Freund’s adjuvant (group 4). Mice were boosted twice at 3-week
intervals. Each group consisted of 4 animals. Three weeks after the
ﬁnal immunization, mice were inoculated with 106TRAMP-C cells
in 100 mL saline intramuscularly. In this experiment (Figure 10),
WT1 peptide immunization did not show any effect on tumor
growth in vivo.
Immunizing mice with syngeneic cancer cells expressing
WT1 can induce antibody to WT1
To determine whether WT1, as naturally expressed by cancer cells,
is immunogenic, B6 mice were immunized with syngeneic
TRAMP-C cells. Mice immunized with TRAMP-C developed
antibody speciﬁc for WT1, as detected by Western immunoblot
analysis, whereas the sera of nonimmunized B6 mice showed no
reaction against theWT1-speciﬁc control (Figure 11). HelperT-cell
responses to WT1 were not evaluated.
Antibodies to WT1 are present in sera of some
patients with AML
As an initial study to begin to evaluate immunity to WT1 in
humans, antibody responses to the WT1 protein were evaluated
using recombinant full-length and truncated WT1-TRX fusion
proteins. Results demonstrated the presence of serum antibodies
Figure 10. Immunization with p117-139 or p130-138 peptide does not prevent
growth of TRAMP-C. Mice were left untreated (group 1) or were given adjuvant only
(group 2), peptide p117-139 (group 3), or peptide p130-138 (group 4). Three weeks
after the ﬁnal immunization, mice were inoculated with 106 TRAMP-C cells.
Figure 9. Evaluation of the potential 9mer CTL epitope within p117-139. The
p117-139 tumor-speciﬁc CTL line was tested against peptides within p117-139
containing or lacking an appropriate H-2b class I binding motif and after restimulation
with p126-134 or p130-138. Lines represent the mean percentage speciﬁc lysis and
standard deviations in chromium release assays performed in triplicate with E:T
ratios of 25:1, 5:1, and 1:1. (A) Cytotoxic activity of the p117-139–speciﬁc T-cell line
against the WT1-negative cell line EL-4 pulsed with the peptides p117-139 (EL-4 1
p117-139), p119-127 (EL-4 1 p119-127), p120-128 (EL-4 1 p120-128), p123-131
(EL-4 1 p123-131), p126-134 (EL-4 1 p126-134), p128-136 (EL-4 1 p128-136),
and p130-138 (EL-4 1 p130-138). (B) Cytotoxic activity of the CTL line after
restimulation with p130-138 against EL-4, EL-4 cells pulsed with p117-139 (EL-4 1
p117-139), p130-138 (EL-4 1 p130-128), and the WT1-positive tumor cell lines
BLKSV40 and TRAMP-C.
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18 patients with AML. No WT1-speciﬁc antibodies were detected
in the 2 normal control sera tested (Figure 12).To further verify that
the patient antibody response was directed against WT1 and not
against the TRX fusion part of the protein or possible E coli
contaminant proteins, controls included the TRX protein alone,
puriﬁed in the same manner as the WT1 fusion proteins. No
reactivity against the TRX fusion or possible E coli contaminant
proteins could be detected.
Discussion
Immunologic tolerance to self-proteins can limit the effectiveness
of oncogenic self-proteins as cancer vaccine targets. The level of
immunologic tolerance to self-proteins seems to be related to the
level and location of expression. However, the level of immuno-
logic tolerance to any particular self-protein is best determined by
empiric experimentation. The current data show that the generation
of antibody, helper T-cell, and CTL responses in mice to murine
WT1 is possible. To the extent studied, the level and location of
expression of human and murine WT1 are similar. Murine results
thus predict that immunity to human WT1 might be elicited with
the same ease.
The presence in humans of cancer cells that aberrantly express
oncogenic proteins results in the elicitation of immunity to the
oncogenic proteins in some patients.41,47 The generation of anti-
body immunity to WT1 by immunization of mice to TRAMP-C
predicts that some patients bearing cancers that overexpress WT1
will have immunity toWT1. Initial studies in humans demonstrated
the presence of antibody to WT1 in some patients with AML.
Further studies must be conducted to correlate antibody responses
in patients with AML with levels of WT1 gene and protein
expression and other characteristics ofAMLblasts.
WT1 is an internal protein. Thus, it is assumed that CTLwill be
the most effective effector mechanism for vaccine and T-cell
therapy. Studies showing CTL lysis of TRAMP-C and BLKSV40
provide evidence that WT1 can be presented by MHC class I of
tumor cells in high enough concentrations to be recognized by
WT1-speciﬁc CTL. Antibody and helper T cells might not have
adequate access to the target protein to mediate therapy. CTL
responses speciﬁc for WT1-positive tumor cells were generated by
immunization with a 23-mer peptide containing both CTL and
helper T-cell epitopes. Two 9-mer peptides within the 23-mer
peptide were able to elicit peptide-speciﬁc CTL. Peptide-speciﬁc
CTL need not necessarily lyse cancer cells that express the target
protein. CTL lysis demands that the target WT1 peptides be
endogenously processed and presented in association with tumor
cell MHC class I molecules. Only one 9-mer peptide, p130-138,
was able to elicit CTL capable of lysing cancer cells expressing
WT1, thus showing that p130-138 is a naturally processed WT1
epitope for B6 mice. This observation does not exclude the
possibility of other B6 CTL peptides. P117-139 contained both
CTL and helper T-cell epitopes and elicited helper and CTL
responses. Presumably, T cells responding to the helper T-cell
epitopes provided help for eliciting CTLresponses.
Two murine cell lines, TRAMP-C and BLKSV40, were shown
to express high levels of WT1-speciﬁc mRNA. Both happened to
be initially transformed by SV40. The extent to which expression
of WT1 correlates with SV40 transformation in other cancers has
not been assessed. However, elucidation of the mechanism by
which SV40 transformation results in WT1 overexpression might
help provide insight into the role ofWT1 in transformation and into
when during the course of transformation WT1 overexpression
occurs.
The lack of observable in vivo antitumor effects against WT1
overexpressing TRAMP-C after WT1 peptide immunization may
be caused by the low MHC class I expression of TRAMP-C cells.48
Alternatively, the immune responses to WT1 after WT1 peptide
immunization might be too weak to elicit signiﬁcant in vivo tumor
immunity. Methods to increase the number of WT1-speciﬁc CTL
might prove more effective. Although WT1 is an appealing
candidate tumor antigen, immunologic tolerance to this self-protein
can prevent or dampen the development of immune responses to
WT1. Further experiments are required to better understand the
therapeutic potential of WT1 vaccines in animal models. A recent
report by Oka et al49 showed that mice immunized with WT1
peptide rejected challenges by WT1-expressing tumor cells and
survived for a long time with no signs of auto-aggression by CTL.
WT1 is expressed primarily during fetal development, but it is
present in low amounts in several normal adult tissues, including
kidney (glomerular podocytes), ovary (epithelial cells surrounding
the oocytes), testis (Sertoli cells and rete testis), and spleen cells.4-6
The WT1 gene is also expressed in normal hematopoietic progeni-
tor cells, and the expression is decreased concurrently with the
differentiation of the hematopoietic progenitor cells.50WT1 protein
is overexpressed in leukemic blasts compared to normal CD341
bone marrow cells.11,29 The amount of WT1 mRNA expression
between these CD341 normal cells and leukemic blasts has been
controversial. Our data showing overexpression of WT1 mRNA in
K562 cells and in 6 of 8 patients with AML compared to normal
CD341 cells are in concordance with data reported by Menssen et
al11 and Inoue et al,51 but they are in contrast to data reported by
Maurer et al52 and Fraizer et al.35
Differences in the levels of WT1 expression observed among
investigators might result from the small number of patient samples
Figure 11. Detection of WT1-speciﬁc antibodies in B6 mice immunized with the
WT1-positive tumor cell line TRAMP-C. Mice were inoculated twice at 2-week
intervals by subcutaneous injection with WT1 overexpressing TRAMP-C cells. Three
weeks after the ﬁnal immunization, sera were obtained. Lanes 1, 3, and 5 show the
molecular weight marker (MWM); lanes 2, 4, and 6 show the WT1 polypeptide WT
N180. Primary antibodies used were WT180 in lane 2, sera of nonimmunized B6 mice
in lane 4, and sera of B6 mice immunized with TRAMP-C tumor cells in lane 6.
Figure 12. Detection of WT1-speciﬁc antibodies in sera of patients with AML.
Sera of patients with AML were used in a 1:500 dilution. Lanes 1, 3, and 5 show the
molecular weight marker (MWM); lanes 2, 4, and 6 show the N-terminus portion of the
TRX-WT1 protein. Primary antibodies used were WT180 in lane 2, sera of a healthy
donor in lane 4, and sera of a patient withAMLin lane 6.
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used, and differences in the WT1 gene expression between subsets
of CD341 cells. Studies in a larger number of patients are necessary
to determine the true prevalence and clinical outcome of patients
with leukemia who are overexpressing WT1 compared with those
with normal CD341 cells.
Semiquantitative real-time PCR analyses demonstrated WT1
mRNAoverexpression in the analyzed murine tumors compared to
normal murine PBMC and BM cells. The experiment indicates
similar overexpression of WT1 in human and mouse malignancies
compared to normal PBMC and bone marrow cells. However, the
comparison of human and murine PCR data are limited by the fact
that different PCR primers were used.
Vaccination with WT1 peptides elicited CTL capable of lysing
WT1-positive cancer cells, but vaccination did not induce observ-
able toxicity. Lysis of WT1-positive cells showed that the level of
expression of WT1 peptide/MHC complexes on cancer cells can be
high enough to be targeted by CTL.The lack of toxicity gives a hint
that the normal level of expression of WT1 by the few normal
tissues that express WT1 in the adult may be too low to be
recognized by WT1-speciﬁc CTL. However, formal toxicity stud-
ies were not performed. The possibility exists that T-cell therapy
regimens with WT1 CTL, in the order of magnitude that might be
contemplated for WT1-speciﬁc CTL therapy of leukemia, would
induce autoimmune toxicity.Augmentation of an immune response
to WT1, to the extent necessary to eradicate malignant cells, might
also partially or totally destroy the normal tissues that express small
amounts of the same protein. Empiric toxicity studies must be
performed in mice to assess possible toxicities before contemplat-
ing WT1-speciﬁc CTLtherapy in humans.
Recently published studies by others demonstrated the genera-
tion of leukemia-speciﬁc HLA-A2453 and HLA-A254 restricted
CTL after in vitro priming to WT1 peptides. The leukemia-speciﬁc
CTLdid not inhibit colony formation by normal bone marrow cells
of HLA-A24–positive patients. The murine data presented here are
in accordance with these ﬁndings. The demonstration that immu-
nity to WT1 can be elicited in mice and humans by peptide
immunization supports further evaluation of WT1 as a vaccine and
T-cell therapy target for eventual testing in human leukemia
therapy.
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